Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-03

    Virtual Booth

    An Enquiry

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Trastuzumab Emtansine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Kelun-Biotech Ph3 Data Favors Trastuzumab Botidotin Over T-DM1
    Kelun-Biotech Ph3 Data Favors Trastuzumab Botidotin Over T-DM1

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/kelun-biotech-presents-positive-phase-3-data-for-trastuzumab-botidotin-compared-to-t-dm1-at-2025-esmo-302588701.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer
    Enhertu Cuts Recurrence Risk By 53% In High-Risk Her2 Cancer

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018027927/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-reduced-the-risk-of-disease-recurrence-or-death-by-53-vs.-T-DM1-in-patients-with-high-risk-HER2-positive-early-breast-cancer-following-neoadjuvant-therapy-in-DESTINY-Breast05-Phase-III-trial

    BUSINESSWIRE
    18 Oct 2025
    Share Share
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer
    ENHERTU Shows iDFS Benefit in High-Risk Early Breast Cancer

    29 Sep 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250928521193/en/ENHERTU-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Invasive-Disease-Free-Survival-Versus-T-DM1-in-DESTINY-Breast05-Phase-3-Trial-in-Patients-with-High-Risk-Early-Breast-Cancer-Following-Neoadjuvant-Therapy

    BUSINESSWIRE
    29 Sep 2025
    Share Share
    Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer
    Kadcyla Is the First Targeted Therapy to Show OS Benefit in Breast Cancer

    09 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231208002957/en/Genentech%E2%80%99s-Kadcyla-Is-the-First-Targeted-Therapy-to-Show-Significant-Overall-Survival-Benefit-in-People-With-HER2-Positive-Early-Stage-Breast-Cancer-With-Residual-Invasive-Disease-After-Neoadjuvant-Treatment

    BUSINESSWIRE
    09 Dec 2023
    Share Share
    Seagen says Tukysa combo hits main goal in Phase III breast cancer study
    Seagen says Tukysa combo hits main goal in Phase III breast cancer study

    17 Aug 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230816497169/en

    BUSINESSWIRE
    17 Aug 2023
    Share Share
    ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%
    ENHERTU Achieved Overall Survival, Reducing the Risk of Death by 36%

    07 Dec 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20221207005239/en

    BUSINESSWIRE
    07 Dec 2022
    Share Share